# Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

> **NCT05806931** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 50 (estimated)

## Conditions studied

- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** TAS-102, oxaliplatin, irinotecan with bevacizumab

## Key facts

- **NCT ID:** NCT05806931
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-17
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806931, "Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05806931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*